
Opinion|Videos|January 2, 2025
Pirtobrutinib in the BRUIN CLL-321 Study
Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as shown in the BRUIN CLL-321 trial results.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- During the 2024 American Society of Hematology annual meeting, the phase 3 BRUIN CLL-321 study looking at the noncovalent BTK inhibitor pirtobrutinib was presented. Provide a brief review of the methodology of the BRUIN CLL-321 study.
- What key takeaways from BRUIN CLL-321 suggest pirtobrutinib’s potential to address unmet needs in heavily pretreated relapsed/refractory CLL patients?
- How does the tolerability data from BRUIN CLL-321 inform strategies for managing adverse events in patients receiving pirtobrutinib?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation
4
Prospective Evidence Supports Tumor-First Multigene Testing in Ovarian Cancer
5
















































